text

Pipeline

content-image

Our oncology pipeline includes multiple genetic medicines designed to reprogram the immune system against cancer

Our in vivo chimeric antigen receptor (CAR) vector generates potent T cells and NK cells targeted against B-cell malignancies directly within the patient’s body. Our dual-payload immunocytokine vectors deliver cancer-killing and immune-activating genes that work together to release patient-specific neoantigens and induce the immune system to activate a persistent and systemic response against the cancer.

Pipeline

Candidate

Indication

Discovery

Preclinical

IND-
Enabling

IND

Clinical - Phase 1

Candidate
GEN-310
In Vivo CAR-T/NK
Indication
B Cell Malignancies
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase 1
Candidate
GEN-1013
IL-12/HSV-eTK
Indication
Solid Tumors
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase 1
Candidate
GEN2
HSV-eTK/GM-CSF
Indication
Solid Tumors
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase 1
Product carrying an armored Chimeric Antigen Receptor (CAR) as therapeutic genes to create CAR-T and CAR-NK cells.
Product carrying an immunocytokine, Interleukin 12 (IL-12) as therapeutic genes and proprietary pro-drug facilitated cancer killing gene, Herpes Simplex Virus enhanced Thymidine Kinase (HSV-eTK).
Product carrying an immunocytokine, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as therapeutic genes and proprietary pro-drug facilitated cancer killing gene, Herpes Simplex Virus enhanced Thymidine Kinase (HSV-eTK).